Unknown

Dataset Information

0

Treatment of chronic hepatitis B in sub-Saharan Africa: 1-year results of a pilot program in Ethiopia.


ABSTRACT: BACKGROUND:The World Health Organization has set an ambitious goal of eliminating viral hepatitis as a major public health threat by 2030. However, in sub-Saharan Africa, antiviral treatment of chronic hepatitis B (CHB) is virtually unavailable. Herein, we present the 1-year results of a pilot CHB treatment program in Ethiopia. METHODS:At a public hospital in Addis Ababa, CHB patients were treated with tenofovir disoproxil fumarate based on simplified eligibility criteria. Baseline assessment included liver function tests, viral markers, and transient elastography (Fibroscan). Changes in laboratory markers were analyzed using Wilcoxon signed-rank tests. Adherence to therapy was measured by pharmacy refill data. RESULTS:Out of 1303 patients, 328 (25.2%) fulfilled the treatment criteria and 254 (19.5%) had started tenofovir disoproxil fumarate therapy prior to September 1, 2016. Of the patients who started therapy, 30 (11.8%) died within the first year of follow-up (28 of whom had decompensated cirrhosis), 9 (3.5%) self-stopped treatment, 7 (2.8%) were lost to follow-up, and 4 (1.6%) were transferred out. In patients who completed 12 months of treatment, the median Fibroscan value declined from 12.8 to 10.4 kPa (p ?1,000,000 IU/mL; adjusted OR 2.41; 95% CI 1.04-5.55) and suboptimal adherence (

SUBMITTER: Desalegn H 

PROVIDER: S-EPMC6296040 | biostudies-literature | 2018 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

Treatment of chronic hepatitis B in sub-Saharan Africa: 1-year results of a pilot program in Ethiopia.

Desalegn Hailemichael H   Aberra Hanna H   Berhe Nega N   Mekasha Bitsatab B   Stene-Johansen Kathrine K   Krarup Henrik H   Pereira Andre Puntervold AP   Gundersen Svein Gunnar SG   Johannessen Asgeir A  

BMC medicine 20181217 1


<h4>Background</h4>The World Health Organization has set an ambitious goal of eliminating viral hepatitis as a major public health threat by 2030. However, in sub-Saharan Africa, antiviral treatment of chronic hepatitis B (CHB) is virtually unavailable. Herein, we present the 1-year results of a pilot CHB treatment program in Ethiopia.<h4>Methods</h4>At a public hospital in Addis Ababa, CHB patients were treated with tenofovir disoproxil fumarate based on simplified eligibility criteria. Baselin  ...[more]

Similar Datasets

2014-02-20 | GSE52791 | GEO
| S-EPMC5637891 | biostudies-literature
| S-EPMC3993620 | biostudies-literature
2022-12-31 | GSE180119 | GEO
| S-EPMC7653283 | biostudies-literature
| S-EPMC6853313 | biostudies-literature
2014-02-20 | E-GEOD-52791 | biostudies-arrayexpress
| S-EPMC5477340 | biostudies-literature
| S-EPMC5533598 | biostudies-other
| S-EPMC8582340 | biostudies-literature